已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

医学 二肽基肽酶-4抑制剂 安慰剂 药效学 药代动力学 2型糖尿病 内科学 体质指数 人口 2型糖尿病 糖尿病 二肽基肽酶-4 内分泌学 胃肠病学 药理学 替代医学 环境卫生 病理
作者
Carol Addy,Daniel Tatosian,Xiaoli S. Glasgow,Isaias Noel Gendrano,Eunkyung Kauh,Ashley Martucci,Amy O. Johnson‐Levonas,Diana Selverian,Catherine Matthews,Marie Gutierrez,John A. Wagner,S. Aubrey Stoch
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:38 (3): 516-530 被引量:25
标识
DOI:10.1016/j.clinthera.2015.12.020
摘要

Omarigliptin (MK-3102) is a potent, oral, long-acting dipeptidyl peptidase (DPP)-4 inhibitor approved in Japan and in global development as a once-weekly treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) effects of omarigliptin in obese participants with and without T2DM.This was a Phase I, randomized, double-blind, placebo-controlled, multiple-dose study of 50-mg omarigliptin administered once weekly for 4 weeks. Participants included 24 obese but otherwise healthy subjects (panel A; omarigliptin, n = 18; placebo, n = 6) and 8 obese patients with T2DM (treatment naive, hemoglobin A1c ≥ 6.5% and ≤ 10.0% [panel B]; omarigliptin, n = 6; placebo, n = 2). Participants were 45 to 65 years of age with a body mass index of ≥ 30 and ≤ 40 kg/m(2). Blood sampling occurred at select time points, depending on the study panel, to evaluate the PK properties of omarigliptin, DPP-4 activity, active glucagon-like peptide 1 levels, and plasma glucose concentrations. Body weight was an exploratory end point. Due to sparse sampling in panel A, a thorough PK analysis was performed in obese patients with T2DM (panel B) only. PD analyses were performed in the overall study population (pooled panels A and B).PK profiles in obese participants with and without T2DM were similar to those observed in nonobese reference subjects (historical data). Steady state was achieved after 1 or 2 weekly doses in obese participants with and without T2DM. In obese patients with T2DM, omarigliptin was rapidly absorbed, with a median Tmax of 1 to 2.5 hours (days 1 and 22). Compared with those in reference subjects, the geometric mean ratios (95% CI) (Obese T2DM/reference) for steady-state plasma AUC0-168h, Cmax, and C168h were 0.80 (0.65-0.98), 0.86 (0.53-1.41), and 1.08 (0.88-1.33), respectively. Trough DPP-4 activity was inhibited by ~90%; postprandial (PP) 4-hour weighted mean active GLP-1 concentrations were increased ~2-fold; and PP glucose was significantly reduced with omarigliptin versus placebo in the pooled population. Omarigliptin was generally well-tolerated in the pooled population, and there were no hypoglycemic events. Consistent with other DPP-4 inhibitors, omarigliptin had no effect on body weight in this short-duration study.The administration of omarigliptin was generally well-tolerated in obese participants with and without T2DM, and the favorable PK and PD profiles support once-weekly dosing. Omarigliptin may provide an important once-weekly treatment option for patients with T2DM. ClinicalTrials.gov identifier: NCT01088711.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
希望天下0贩的0应助sigrid采纳,获得10
4秒前
完美世界应助淡定的半梦采纳,获得10
7秒前
ding应助很好采纳,获得10
7秒前
bing发布了新的文献求助10
8秒前
10秒前
弧光完成签到 ,获得积分0
10秒前
bing完成签到,获得积分10
12秒前
HLZ发布了新的文献求助10
14秒前
lmk完成签到 ,获得积分10
17秒前
24秒前
踏实的碧空完成签到 ,获得积分10
24秒前
压缩完成签到 ,获得积分10
27秒前
很好发布了新的文献求助10
29秒前
缓慢的灵枫完成签到 ,获得积分10
31秒前
33秒前
35秒前
NexusExplorer应助Milesgao采纳,获得10
37秒前
lanze发布了新的文献求助10
39秒前
水若琳发布了新的文献求助10
40秒前
早睡早起身体好完成签到,获得积分10
40秒前
白杨木影子被拉长完成签到,获得积分10
42秒前
YYYCCCCC完成签到,获得积分10
43秒前
眼睛大的薯片完成签到 ,获得积分10
44秒前
lunar完成签到 ,获得积分10
54秒前
高大的蜡烛完成签到,获得积分10
59秒前
芜湖起飞完成签到 ,获得积分10
1分钟前
肃肃其羽完成签到 ,获得积分10
1分钟前
山城小肘子完成签到,获得积分10
1分钟前
陈尹蓝完成签到 ,获得积分10
1分钟前
淡定的半梦完成签到,获得积分10
1分钟前
HLZ完成签到,获得积分20
1分钟前
哈哈环完成签到 ,获得积分10
1分钟前
阿亞完成签到,获得积分10
1分钟前
yunjian1583完成签到,获得积分10
1分钟前
多多完成签到,获得积分10
1分钟前
redamancy完成签到 ,获得积分10
1分钟前
Vaseegara完成签到 ,获得积分10
1分钟前
旷野发布了新的文献求助10
1分钟前
上官若男应助科研通管家采纳,获得10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989989
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256053
捐赠科研通 3270900
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216